Amgen Competitive Strategy & Market Position

They also require precision-engineered manufacturing infrastructure, the kind of capital moat that a startup competitor simply cannot build in five years regardless of how much venture funding it raises. Amgen competes in a pharmaceutical landscape that has become more crowded and complex than the relatively unchallenged terrain it occupied in the 1990s. Its primary competitors vary by therapeutic category: in inflammation and rheumatology, it faces AbbVie (Humira, Rinvoq, Skyrizi), Pfizer (Xeljanz, Cibinqo), Johnson & Johnson (Stelara, Tremfya), and Eli Lilly (Taltz, Olumiant). In cardiovascular lipid management, Novartis's inclisiran, a twice-yearly injectable RNA interference therapy, represents a mechanistically distinct but commercially overlapping competitor to Repatha. In oncology, Amgen competes with Roche/Genentech, Bristol Myers Squibb, AstraZeneca, and Merck across various tumor types. Here, Amgen competes against Pfizer, Samsung Bioepis (a South Korean company), and Sandoz (spun out of Novartis in 2023) for market share in products like adalimumab, bevacizumab, and trastuzumab biosimilars. Amgen's competitive positioning relative to Eli Lilly deserves particular attention given the obesity drug race. Amgen's MariTide, currently in Phase 3 development, deploys a bispecific peptide-antibody conjugate mechanism that theoretically offers once-monthly dosing versus weekly injections for GLP-1 receptor agonists, a differentiation point that could matter significantly to patients managing chronic obesity. Krystexxa, which treats refractory gout, competes with dose escalation of standard urate-lowering therapies and with emerging URAT1 inhibitors, though its unique mechanism as a pegylated uricase provides genuine clinical differentiation for the most severe patient populations. Differentiating MariTide on efficacy, tolerability, dosing convenience, or patient outcomes will require compelling Phase 3 data and a commercial infrastructure capable of competing against two of the world's largest pharmaceutical companies in a market that has become the most intensely competitive therapeutic battleground in drug industry history. Amgen has been doing this continuously since the early 1980s, accumulating process knowledge, validated manufacturing infrastructure, and regulatory relationships that no competitor can rapidly replicate. This manufacturing moat is particularly relevant in the biosimilars segment, where Amgen applies the same expertise it used to build its branded business to produce competitor products at lower cost. Amgen's standing in the oncology and nephrology communities, built since Epogen launched in 1989 through sales relationships and clinical data, creates switching costs that market share statistics understate. This financial scale means Amgen can fail in multiple pipeline programs simultaneously without existential consequences, a resilience that shapes its risk appetite favorably relative to competitors. Amgen's biosimilars generated about US$3.0 billion of fiscal 2025 sales, but the mix is shifting away from its first-mover adalimumab product: Amjevita and Amgevita fell 22% to US$597 million, while Pavblu (aflibercept) contributed US$700 million and Wezlana and Wezenla (ustekinumab) US$273 million. The biosimilar business, Amgen's own copies of competitor branded biologics, generated volume growth at lower margins than branded products but provided a hedge against the same competitive pressure the company faces from biosimilars to its own drugs.